Abstract:Amyotrophic lateral sclerosis (ALS) is an intractable disease that causes respiratory failure leading to mortality. The main locus of ALS is motor neurons. The success of antisense oligonucleotide (ASO) therapy in spinal muscular atrophy (SMA), a motor neuron disease, has triggered a paradigm shift in developing ALS therapies. The causative genes of ALS and disease-modifying genes, including those of sporadic ALS, have been identified one after another. Thus, the freedom of target choice for gene therapy has expanded by ASO strategy, leading to new avenues for therapeutic development. Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO for ALS. Improving protocols and devising early interventions for the disease are vital. In this review, we updated the knowledge of causative genes in ALS. We summarized the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma (FUS), and transacting response DNA-binding protein. The frequency of the C9ORF72 mutation is low in Japan, unlike in Europe and the United States, while SOD1 and FUS are more common, indicating that the target mutations for gene therapy vary by ethnicity. A genome-wide association study has revealed disease-modifying genes, which could be the novel target of gene therapy. The current status and prospects of gene therapy development were discussed, including ethical issues. Furthermore, we discussed the potential of axonal pathology as new therapeutic targets of ALS from the perspective of early intervention, including intra-axonal transcription factors, neuromuscular junction disconnection, dysregulated local translation, abnormal protein degradation, mitochondrial pathology, impaired axonal transport, aberrant cytoskeleton, and axon branching. We simultaneously discuss important pathological states of cell bodies: persistent stress granules, disrupted nucleocytoplasmic transport, and cryptic splicing. The development of gene therapy based on the elucidation of disease-modifying genes and early intervention in molecular pathology is expected to become an important therapeutic strategy in ALS.

Therapeutic tools for familial ALS

Treatment of hereditary amyotrophic lateral sclerosis

Gene therapy for ALS: A review

Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy

Molecular mechanisms of amyotrophic lateral sclerosis as broad therapeutic targets for gene therapy applications utilizing adeno-associated viral vectors

Cell and gene therapy for amyotrophic lateral sclerosis

Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy

New developments in pre-clinical models of ALS to guide translation

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update

Cell therapy in ALS: An update on preclinical and clinical studies

Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives

Current State and Future Directions in the Therapy of ALS

Amyotrophic lateral sclerosis: translating genetic discoveries into therapies

Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent

Novel therapeutic targets for amyotrophic lateral sclerosis: ribonucleoproteins and cellular autonomy

Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen

Improving clinical trial outcomes in amyotrophic lateral sclerosis